Clinical Trial Detail

NCT ID NCT02164240
Title Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

gastrointestinal stromal tumor

Therapies

Sunitinib

Regorafenib

Age Groups: adult

No variant requirements are available.